About Quarterly Earnings Report Disclosures
| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥45.83B | ¥42.47B | +7.9% |
| Cost of Sales | ¥23.14B | ¥21.07B | +9.8% |
| Gross Profit | ¥22.69B | ¥21.40B | +6.0% |
| SG&A Expenses | ¥29.52B | ¥19.62B | +50.5% |
| Operating Income | ¥-6.84B | ¥1.78B | -483.9% |
| Non-operating Income | ¥1.40B | ¥786M | +78.1% |
| Non-operating Expenses | ¥184M | ¥330M | -44.2% |
| Ordinary Income | ¥-5.62B | ¥2.24B | -351.3% |
| Profit Before Tax | ¥9.41B | ¥7.16B | +31.4% |
| Income Tax Expense | ¥1.53B | ¥1.91B | -19.6% |
| Net Income | ¥7.88B | ¥5.25B | +50.0% |
| Net Income Attributable to Owners | ¥7.78B | ¥5.25B | +48.3% |
| Total Comprehensive Income | ¥10.00B | ¥1.45B | +591.2% |
| Depreciation & Amortization | ¥2.25B | ¥2.28B | -1.2% |
| Interest Expense | ¥13M | ¥9M | +44.4% |
| Basic EPS | ¥186.81 | ¥118.75 | +57.3% |
| Dividend Per Share | ¥45.00 | ¥45.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥119.88B | ¥106.98B | +¥12.90B |
| Cash and Deposits | ¥36.32B | ¥25.17B | +¥11.15B |
| Accounts Receivable | ¥28.34B | ¥29.65B | ¥-1.31B |
| Inventories | ¥13.18B | ¥13.71B | ¥-528M |
| Non-current Assets | ¥141.25B | ¥137.08B | +¥4.17B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥7.99B | ¥2.77B | +¥5.21B |
| Financing Cash Flow | ¥-7.66B | ¥-1.96B | ¥-5.70B |
| Item | Value |
|---|---|
| Book Value Per Share | ¥5,099.32 |
| Net Profit Margin | 17.0% |
| Gross Profit Margin | 49.5% |
| Current Ratio | 357.0% |
| Quick Ratio | 317.8% |
| Debt-to-Equity Ratio | 0.23x |
| Interest Coverage Ratio | -525.92x |
| EBITDA Margin | -10.0% |
| Effective Tax Rate | 16.3% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +7.9% |
| Operating Income YoY Change | -11.6% |
| Ordinary Income YoY Change | -35.4% |
| Net Income Attributable to Owners YoY Change | +48.3% |
| Total Comprehensive Income YoY Change | +590.9% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 46.54M shares |
| Treasury Stock | 5.09M shares |
| Average Shares Outstanding | 41.67M shares |
| Book Value Per Share | ¥5,129.35 |
| EBITDA | ¥-4.58B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥45.00 |
| Year-End Dividend | ¥55.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| InformationService | ¥1.39B | ¥407M |
| PharmaceuticalProducts | ¥38.35B | ¥-7.50B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥95.50B |
| Operating Income Forecast | ¥-2.60B |
| Ordinary Income Forecast | ¥-1.10B |
| Net Income Attributable to Owners Forecast | ¥12.70B |
| Basic EPS Forecast | ¥305.56 |
| Dividend Per Share Forecast | ¥60.00 |
This data was automatically extracted from XBRL files. Please refer to the original disclosure documents for accuracy.
| Property, Plant & Equipment | ¥29.76B | ¥27.07B | +¥2.69B |
| Intangible Assets | ¥2.00B | ¥1.89B | +¥111M |
| Investment Securities | ¥86.94B | ¥84.87B | +¥2.08B |
| Total Assets | ¥261.12B | ¥244.06B | +¥17.07B |
| Current Liabilities | ¥33.58B | ¥16.58B | +¥17.00B |
| Accounts Payable | ¥7.76B | ¥4.60B | +¥3.15B |
| Short-term Loans | ¥1.27B | ¥1.28B | ¥-10M |
| Non-current Liabilities | ¥14.92B | ¥17.35B | ¥-2.43B |
| Total Liabilities | ¥48.50B | ¥33.93B | +¥14.57B |
| Total Equity | ¥212.62B | ¥210.13B | +¥2.50B |
| Capital Stock | ¥24.36B | ¥24.36B | ¥0 |
| Capital Surplus | ¥24.24B | ¥24.23B | +¥17M |
| Retained Earnings | ¥132.75B | ¥131.49B | +¥1.26B |
| Treasury Stock | ¥-15.51B | ¥-14.52B | ¥-993M |
| Owners' Equity | ¥211.38B | ¥209.00B | +¥2.38B |
| Working Capital | ¥86.30B | - | - |